Pharmacoeconomic Guidelines: Malaysia

Country/Region: Malaysia
PE Guidelines
Pharmacoeconomic Guideline For Malaysia (March 2012)
Pdf in English
PE Guidelines Source:
Ministry of Health of Malaysia

Information current as of Thursday, April 28, 2016

Key Features

Type of Guidelines PE Guidelines
Title and year of the document Pharmacoeconomic Guideline For Malaysia 2012
Purpose of the document A methodological guide to conduct pharmacoeconomic analysis in Malaysia.
Standard reporting format included Yes
Disclosure Yes
Target audience of funding/ author's interests Both public and private payers, healthcare industries, clinicians, and research communities, accordingly.
Perspective Provider or funder. Patient and societal perspective are encouraged
Indication Indication(s) must be approved by DCA/reference country
Target population Must be clearly stated.
Subgroup analysis Yes, can be included when appropriate
Choice of comparator To be compared against the most relevant alternatives for the proposed indication in the applied setting. Comparator(s) should not be a placebo but non-drug therapy can be used. The choice of comparator(s) should always be justified.
Time horizon Should be long enough to capture all changes in cost(s) and outcome(s) of the intervention.
Assumptions required Yes. Should be clearly stated.
Preferred analytical technique CEA and CUA. Technique chosen should be justified clearly.
Costs to be included All costs relevant to the chosen perspective (provider/funder). Societal cost is preferred in any analysis.
Source of costs Local cost data in the applied setting. The source of cost data must be identified.
Modeling Yes. Clearly detailed with maximum transparency. All assumptions should be explicitly stated.
Systematic review of evidences Yes. Meta-analysis is encouraged.
Preference for effectiveness over efficacy N/A
Preferred outcome measure Should justify the selection.
Preferred method to derive utility Should justify the selection.
Equity issues stated N/A
Discounting costs 3% (Sensitivity Analysis, 0 and 5%)
Discounting outcomes 3% (Sensitivity Analysis, 0 and 5%)
Sensitivity analysis-parameters and range All key uncertain parameters. Best and worst case scenario presented.
Sensitivity analysis-methods One-way, multivariate analysis as deemed appropriate.
Presenting results Aggregated and disaggregated form for cost(s) and outcome(s).
Incremental analysis Yes
Total costs vs effectiveness (cost/effectiveness ratio) Yes
Portability of results (Generalizability) N/A
Financial impact analysis Yes
Mandatory or recommended or voluntary Voluntary for 2 years upon launch of the pharmacoeconomic guideline and mandatory thereafter.


The ISPOR Malaysia Chapter (MySPOR) contributed to the key feature form.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now